
TLO Toolbox: Hammer Out Successful License Agreements and Avoid Terminal Disclaimer Problems

July 30, 2020

Andy Curtin Deirdre Sanders Rebecca Simmons, Ph.D.







Presenters



Andy Curtin

Director of Intellectual Property, Northeastern University



Deirdre Sanders

Principal, Hamilton Brook Smith Reynolds



Rebecca Simmons, Ph.D.

Associate, Hamilton Brook Smith Reynolds





Hamilton Brook Smith Reynolds

2 Offices



Boston
Seaport Innovation District



Concord
Route 128 Technology Corridor

1980

Year Founded

Broad Spectrum of Technology Specialties

Artificial Intelligence

Autonomous Vehicles Bioinformatics Biotechnology & Life Sciences **Biologics & Immunotherapeutics** Blockchain **Chemical Engineering Pharmaceuticals** Chemistry **Material Sciences** Clean Technology **Medical Devices** Medical Imaging Mechanical Engineering **Electrical Engineering** Semiconductors **Optics** Robotics Mobile Internet of Things Network Infrastructure **Telecommunications** Computer Hardware **Computer Software**

Business Methods

35

Attorneys,
Patents Agents,
Technology Specialists

Numerous

Firm accolades since 2010, including:





Andy Curtin

Director of Intellectual Property, Northeastern University



- Over 20 years of intellectual property experience
- Served as Senior IP Counsel for the Enterprise and Imaging Divisions of Nuance Communications,
 Senior Patent Counsel at 3Com Corporation, and
 Patent Counsel at Mitsubishi Electric Research Labs







The CRI team is agile and responsive – focused on the translation of University innovations into tangible solutions through licenses, spinouts and collaborations.

Our dedication to establishing ongoing dialogue with industry informs Northeastern's progressive research, enabling a productive balance between exploration and implementation.

https://www.northeastern.edu/cri/





Technology Licensing Officer (TLO) Toolbox



Terminal Disclaimers

Exclusive Patent Licenses

Non-Exclusive Patent Licenses

Joint Research Agreements

Inter-Institutional Agreements

Patent Assignments





Deirdre Sanders

Principal, Hamilton Brook Smith Reynolds



- 25 years of law firm experience
- State Legislative experience
- University teaching experience
- Immediate Past President, Boston Patent Law Association
- Science expertise in monoclonal antibodies, immuno-oncology, genetics, therapeutic methods, diagnostic methods, biotherapeutics, vaccines, etc.
- Litigation experience: Federal District Court Trials,
 Federal Circuit Appeals





Risk of Impacting Rights

Owner A Owners A and B Owner B Obviousness-Patent **Patent** Patent Type Double Claim A Claim A' Claim B **Patenting** Rejection Licensee A Licensees A and B Licensee B

Rights of an Owner or a Licensee will be impacted.





Double Patenting Rejections

There are generally two types of double patenting rejections:

A "same invention" type double patenting rejection is based on 35 U.S.C. 101, which states in the singular that an inventor "may obtain <u>a</u> patent."

A "nonstatutory-type" double patenting rejection is based on a judicially created doctrine grounded in public policy and which is primarily intended to prevent prolongation of the patent term by prohibiting claims in a second patent not patentably distinct from claims in a first patent.





Options for Overcoming Double Patenting Rejections

- Terminal Disclaimers common ownership required
- Arguments
- Claim Amendments
- Claim Cancellations
- Application Abandonment

Consider potential effect on co-owner or licensee





Input to Patent Counsel

Patent Manager Input


- Subject Matter
- Target Market
- Ownership
- License Commitments

Patent Counsel Recommendations

Global Application Strategy

- Claim types
- Serial or Parallel Filings
- 1st Filing U.S. or PCT





U.S. Application Claim Types Flexibility

Life Sciences

- Compounds
- Compositions
- Methods of Treatment
- Methods of Diagnosis
- Methods of Detection
- Methods of Manufacture
- Kits

Medical Devices/Engineering

- Apparatus
- Means-plus-function
- Method of Use
- Method of Manufacture
- Computer Readable Medium
- Software as a Service (SaaS)
- Kits





Parallel Filings

Omnibus Application (All Subject Matters)

Omnibus Application (All Subject Matters)

Omnibus Application (All Subject Matters)

Ownership based on claims

Composition Claims

Method of Treatment A

Method of Treatment A'


Double Patenting **Terminal** Disclaimer?

Rejection





Parallel Filings










Serial Filings – Continuation Applications

Omnibus Application (All Subject Matters)

Common
Ownership of
all Applications








Serial Filings – Continuation Applications

Omnibus Application (All Subject Matters)

Not Common
Ownership of
all Applications







Serial Filings – Divisional Applications

Omnibus Application
(All Subject Matters)

Treatment A Claims

Issued
Patent

Omnibus Application
(All Subject Matters)

Treatment A Claims

Issued
Patent

Treatment B Claims

Safe Harbor (35 U.S.C. § 121)





Restriction Requirement

Invention Group I (elected) Inventor A Owner A
Invention Group II (withdrawn/cancelled) Inventor B Owner B

Effect on Owner B


Effect on Licensee of Group II claims





Terminal Disclaimers – Typical Considerations

- Terminal Disclaimers overcome an obviousness-type double patenting rejection in exchange for matching end of term with patent that formed the basis of rejection
- Applications must be co-owned throughout patent term








Terminal Disclaimers – Advanced Considerations

- Are earlier issued claims obvious over later issuing claims (i.e., does double patenting apply)?
- Earlier issued patent is invalid until Terminal Disclaimer is filed, if Terminal Disclaimer is needed.
- Patent with Terminal Disclaimer ends at same time as other patent, even if term is lost in earlier issued patent. (Gilead)
- Terminal Disclaimers may affect the duration of a license -- patent owner cannot charge royalties after the patent expires (*Marvel*)







Strategic Agreements or Filings Reduce Risk of Impacting Rights

Owner A

Owners A and B

Owner B

Patent Claim A Patent Claim A'

Patent Claim B

Licensee A

Licensees A and B


Licensee B





Rebecca Simmons, Ph.D.

Associate, Hamilton Brook Smith Reynolds



- Over 10 years of law firm experience
- Organic Chemistry Background
- Ph.D. Degree, Chemistry
- Harvard University, Ph.D.
- Boston University Law School, J.D.
- Experience with the preparation and prosecution of both U.S. and foreign patents involving small molecules
- Practices in areas of pharmaceuticals, chemistry, and biotechnology






Exclusive Patent Licenses

- In an exclusive patent license, a licensor agrees not to practice the invention or grant other exclusive licenses to other licensors in a specified field and/or territory
- An exclusive patent license can, but need not, confer independent standing to sue under a patent
- An exclusive patent license that confers independent standing to sue is a *de facto* assignment of the patent





Exclusive Patent Licenses and Ownership



Does Owner co-own Patents A and B or does the exclusive license operate as a *de facto* assignment of Patent A?

 An exclusive patent license that transfers "all substantial rights" in a patent is a de facto assignment of the patent





"All Substantial Rights"

- Rights that, once relinquished, result in de facto assignment of the patent
 - Exclusive Right to Make, Use and Sell Under the Patent;
 - Right to Control (Past, Present and Future) Litigation Decisions;
 - Right to Sublicense;
 - Reversionary Interest;
 - Right to Exclude in All Field(s) of Use; and
 - Right to Assign





Insubstantial Rights

- Rights that, though retained, are insufficient to foreclose de facto assignment
 - Financial Interests, including royalties and damages sharing
 - Notification Rights
 - Limited Control Over Sublicensing
 - Termination Provisions, especially when associated with a selfrenewing provision or predicated on license breach
 - Territorial Limitations (e.g., ex-U.S.)
 - Right to Make, Sell and Use, especially when retained by a nonpracticing entity





Substantial Rights

- Right to Sue, when retained, is sufficient to foreclose de facto assignment
 - Right to bring suit, even when right is secondary to licensee's right to bring suit
 - E.g., "In the event that Licensee is unsuccessful in persuading the alleged infringer to desist or fails to initiate an infringement action within a reasonable time after Licensee first becomes aware of the basis for such action, Licensor shall have the right, at its sole discretion, to prosecute such infringement..."





Substantial Rights

- Right to Sue, when retained, is sufficient to foreclose de facto assignment
 - Right to join lawsuit alleging infringement of the licensed patent
 - E.g., "Licensor shall have the right to participate in any action to prosecute any Third Party infringement of the Patent Rights in the relevant Field in the Territory through its own counsel."
 - Consultation rights
 - E.g., "Prior to commencing any such action, Licensee will
 consult with Licensor and shall consider the views of Licensor..."
 - Veto rights/Right to consent





Multi-Party Interests In Patent Prosecution

- AUTM's Model Inter-institutional Agreement (MIIA)
 - Divides rights amongst a Lead Institution and Other Institution(s)
 - Nearly all patent prosecution and licensing authority lies with the Lead Institution
 - Other Institution(s) retain limited rights, such as the right to license patent rights to other non-profit research institutions for research and educational purposes
- Clarity results from assigning roles
- Be the Lead, when possible





Multi-Party Interests in Patent Litigation

- AUTM's MIIA not designed to address patent litigation
- Exclusive Patent Licenses
 - Retaining "substantial rights" often delegates rights and duties related to patent litigation
- Joint Research Agreements






Joint Research Agreements


- To be effective, a JRA must be in effect **on or before** the effective filing date of the claimed invention
- Inventions subject to the JRA are deemed to be commonly owned
 - A terminal disclaimer filed in reliance on a JRA must include a provision waiving the right to separately enforce the disclaimed patent and reference patent(s)
 - Separate enforcement of the disclaimed patent and reference patent(s) renders the disclaimed patent unenforceable





JRAs and Patent Enforcement





Because Terminal Disclaimers predicated on a JRA must include a <u>waiver</u> to enforce separately, JRAs should address enforcement issues





JRAs and Patent Enforcement

- Right to File a Terminal Disclaimer in Reliance on the JRA
- Right to Notice of Owner B's Terminal Disclaimer
- Right to Consent to Owner B's Terminal Disclaimer
- Enforcement Considerations
 - Right to Sue/Right to Indulge Infringement
 - Right to Notice of Owner B's Enforcement Action
 - Right to Consent to Owner B's Enforcement Action
 - Owner B's Obligation to Sue/Owner B's Right to Indulge Infringement
 - Rules of Joinder





Technology Licensing Officer (TLO) Toolbox







For more information ...



Andy Curtin
Director of Intellectual Property,
Northeastern University

A.Curtin@northeastern.edu



Deirdre Sanders
Principal,
Hamilton Brook Smith Reynolds
(978) 341-0036
Deirdre.Sanders@hbsr.com



Rebecca Simmons, Ph.D.
Associate,
Hamilton Brook Smith Reynolds
(978) 341-0036
Rebecca.Simmons@hbsr.com



